ライフサイエンスコーパス: ceftazidime

1 me, and ceftriaxone, and 1 for cefazolin and ceftazidime).

2 d false resistance (aztreonam, cefepime, and ceftazidime).

3 ithout the antibiotic treatment (imipenem or ceftazidime).

4 e, result in 10-fold increased hydrolysis of ceftazidime.

5 ophthalmitis are intravitreal vancomycin and ceftazidime.

6 iants have emerged that confer resistance to ceftazidime.

7 ii by BOCILLIN FL, aztreonam, meropenem, and ceftazidime.

8 cin, and 81.5% (53/65) received intravitreal ceftazidime.

9 t beta-lactam antibiotics, carbenicillin and ceftazidime.

10 imino-cephalosporins, such as cefotaxime and ceftazidime.

11 d susceptible to cefotaxime, ceftriaxone, or ceftazidime.

12 and smlt0009 mutants have reduced uptake of ceftazidime.

13 ration cephalosporins such as cefotaxime and ceftazidime.

14 oximino cephalosporins such as cefotaxime or ceftazidime.

15 level resistance to the structurally similar ceftazidime.

16 eftazidime, or isotype control antibody with ceftazidime.

17 he absence of simultaneous administration of ceftazidime.

18 plus amoxicillin-clavulanate or intravenous ceftazidime.

19 sporins (ESOCs), for example, cefotaxime and ceftazidime.

20 cefotaxime but not to the related antibiotic ceftazidime.

21 e combination of intravitreal vancomycin and ceftazidime.

22 th injection of intravitreous vancomycin and ceftazidime.

23 nly a modest 25% increase in k(cat)/K(m) for ceftazidime (0.015-->0.019 mum(-1) s(-1)).

24 every 6 hrs, cefepime 1 g every 12 hrs, and ceftazidime 1 g every 8 hrs with target attainments of 9

25 anisms, susceptibilities were the following: ceftazidime, 100%; levofloxacin, 100%; ciprofloxacin, 95

26 d by carbapenems (20%), TMP-SMX (18.5%), and ceftazidime (11%).

27 ztreonam, >128 microg/ml versus 4 microg/ml; ceftazidime, 128 microg/ml versus 2 microg/ml; piperacil

28 Ceftazidime 1g every 8 hrs and ciprofloxacin produce low

29 9.9%, followed by cefepime 2 g every 12 hrs, ceftazidime 2 g every 8 hrs, piperacillin/tazobactam 4.5

30 d-inject procedures with vancomycin 1 mg and ceftazidime 2 mg.

31 Meropenem, imipenem, cefepime, ceftazidime (2 g every 8 hrs), and piperacillin/tazobact

32 g/8 hours) plus daptomycin (6 mg/kg/day) or ceftazidime (2 g/8 hours).

33 na vitrectomy with intravitreal injection of ceftazidime (2 mg/0.1 ml) and amikacin (0.4 mg/0.1 ml) w

34 I) and BHI plus vancomycin (6 microg/ml) and ceftazidime (2 microg/ml) (BHIVC).

35 th 5% sheep blood, vancomycin (6 microg/ml), ceftazidime (2 microg/ml), amphotericin B (2 microg/ml),

36 he 94 gram-negative organisms tested against ceftazidime, 2 were of intermediate sensitivity and 6 we

37 ent with carbapenems (36/206 [17.5%]) versus ceftazidime (25/201 [12.4%]) and piperacillin-tazobactam

38 Of the 53 patients who received intravitreal ceftazidime, 46 (86.8%) had allergies to PCNs alone, 5 (

39 E. coli 018:K1 in the presence or absence of ceftazidime (50 mg/kg intravenously).

40 for cefepime; 44 and 43%, respectively, for ceftazidime; 71 and 19%, respectively, for imipenem; and

41 elebactam, 91.5%, 0.25 mug/ml, and 2 mug/ml; ceftazidime, 77.1%, 4 mug/ml, and 64 mug/ml; meropenem,

42 omitant 4-fold increase in the resistance to ceftazidime, a third-generation cephalosporin.

43 ctamase activity that increased tolerance to ceftazidime, a widely used beta-lactam antibiotic.

44 Molecular dynamics simulations of KPC:ceftazidime acyl-enyzmes reveal that the deacylation gen

45 less pronounced in the KPC-4 than the KPC-2 ceftazidime acyl-enzyme and are not observed in the KPC-

46 nt (E166Q) KPC-2 and KPC-4 mutants show that ceftazidime acylation causes rearrangement of three loop

47 ucted to explain these findings suggest that ceftazidime adopts a unique conformation, despite preser

48 had a safety profile consistent with that of ceftazidime alone.

49 onsistent with that previously observed with ceftazidime alone.

50 oncentrations and hydrolytic activity toward ceftazidime, an advanced generation cephalosporin antibi

51 sequence requirements for the hydrolysis of ceftazidime, an extended spectrum cephalosporin commonly

52 ile prediction of resistance was 69%-73% for ceftazidime and 41%-50% for imipenem.

53 ies, were randomly assigned (1:1) to 2000 mg ceftazidime and 500 mg avibactam (by 2 h intravenous inf

54 olderia pseudomallei had subpopulations with ceftazidime and amoxicillin-clavulanate susceptibilities

55 Compounds 2-6 in combinations with ceftazidime and ampicillin were also efficient in restor

56 nt, structurally resembling a hybrid between ceftazidime and cefepime.

57 tests, this cephalothin analogue lowered the ceftazidime and cefotaxime minimum inhibitory concentrat

58 esponsible for the improved activity against ceftazidime and cefotaxime, consistent with observations

59 t one ESC were tested by disk diffusion with ceftazidime and cefotetan disks with and without APBA.

60 1-255 significantly enhanced the activity of ceftazidime and cefpirome against extended-spectrum ceph

61 s (MK-7655 with imipenem, and avibactam with ceftazidime and ceftaroline), new macrolides (cethromyci

62 Comparison of the acyl-enzyme structures of ceftazidime and loracarbef, a beta-lactam substrate, rev

63 Susceptibility to ceftazidime and meropenem occurred in approximately 70%

64 residue and also of Tyr221 that would allow ceftazidime and other third-generation cephalosporins to

65 the susceptibility of Bcc and B. gladioli to ceftazidime and piperacillin is restored in vitro Both t

66 cept for the CTX-M-10-producing E. coli with ceftazidime and the SHV-18-producing K. pneumoniae with

67 ng up to a 64-fold increased activity toward ceftazidime and up to an 8-fold increased resistance to

68 plex with the third-generation cephalosporin ceftazidime and with a transition-state analogue of ceft

69 nded-spectrum beta-lactam antibiotics (e.g., ceftazidime) and beta-lactamase inhibitors (e.g., clavul

70 Moreover, piperacillin, tazobactam, ceftazidime, and avibactam, as well as combinations ther

71 sensitive for the prediction of ceftriaxone, ceftazidime, and aztreonam resistance and 73% (range, 25

72 amase (ESBL) and vancomycin, amphotericin B, ceftazidime, and clindamycin (VACC) plates.

73 sed activity for the oxyimino-cephalosporin, ceftazidime, and decreased activity toward all other bet

74 known binding site for both ceftolozane and ceftazidime, and DNA polymerase.

75 ed high mortality, significant resistance to ceftazidime, and limited use of TMP-SMX.

76 were tested for susceptibility to aztreonam, ceftazidime, and meropenem; Enterobacteriaceae were also

77 isotype control monoclonal antibody without ceftazidime, anti-CD14 monoclonal antibody with ceftazid

78 detect these isolates if both cefotaxime and ceftazidime are tested, but only about half would be cla

79 penem plus daptomycin is more effective than ceftazidime as empirical antibiotic treatment of nosocom

80 e mode of action of the frontline antibiotic ceftazidime at the molecular level.

81 at the test-of-cure visit were similar with ceftazidime-avibactam (140 [91%; 95% CI 85.6-94.7] of 15

82 Of these, 154 assigned to ceftazidime-avibactam (144 with complicated urinary trac

83 treatment-emergent adverse events with both ceftazidime-avibactam (21 [13%] of 164 patients) and bes

84 (1:1) to 5-21 days of treatment with either ceftazidime-avibactam (a combination of 2000 mg ceftazid

85 -lactam/beta-lactamase inhibitor combination ceftazidime-avibactam (CAZ-AVI) among carbapenem-resista

86 six percent of index isolates susceptible to ceftazidime-avibactam (CAZ-AVI) had subsequent P. aerugi

87 Ceftazidime-avibactam (CAZ-AVI) has been approved in Eur

88 tam, as well as piperacillin-tazobactam plus ceftazidime-avibactam (the clinically available counterp

89 /acute pyelonephritis were randomized 1:1 to ceftazidime-avibactam 2000 mg/500 mg every 8 hours or do

90 333 patients were randomly assigned, 165 to ceftazidime-avibactam and 168 to best available therapy.

91 llowed for successful treatment by combining ceftazidime-avibactam and aztreonam.

92 program compared the efficacy and safety of ceftazidime-avibactam and doripenem in patients with com

93 andomized patients, 393 and 417 treated with ceftazidime-avibactam and doripenem, respectively, were

94 Administration of ceftazidime-avibactam and fosfomycin separately signific

95 eptibility analysis revealed synergy between ceftazidime-avibactam and fosfomycin.

96 e carbapenem-NS isolates were susceptible to ceftazidime-avibactam and imipenem-relebactam.

97 results provide evidence of the efficacy of ceftazidime-avibactam as a potential alternative to carb

98 These results support a role for ceftazidime-avibactam as a potential alternative to carb

99 cillin-avibactam and piperacillin-tazobactam-ceftazidime-avibactam combinations restored susceptibili

100 ss the efficacy, safety, and tolerability of ceftazidime-avibactam compared with best available thera

101 produced in Bcc and B. gladioli Previously, ceftazidime-avibactam demonstrated significant potency a

102 We assessed the ceftazidime-avibactam disk diffusion breakpoints that pr

103 llin-tazobactam, ceftolozane-tazobactam, and ceftazidime-avibactam for the treatment of ESBL infectio

104 events occurred in 75 (19%) patients in the ceftazidime-avibactam group and 54 (13%) patients in the

105 51 (31%) of 164 patients in the ceftazidime-avibactam group and 66 (39%) of 168 in the b

106 occurred in 302 (75%) of 405 patients in the ceftazidime-avibactam group versus 299 (74%) of 403 in t

107 pulation, 245 (68.8%) of 356 patients in the ceftazidime-avibactam group were clinically cured, compa

108 Four serious adverse events (all in the ceftazidime-avibactam group) were judged to be treatment

109 57 participants were clinically cured in the ceftazidime-avibactam group, compared with 211 (78.1%) o

110 Ceftazidime-avibactam had a safety profile consistent wi

111 e aimed to assess the efficacy and safety of ceftazidime-avibactam in patients with nosocomial pneumo

112 Ceftazidime-avibactam is a potential new agent for use i

113 When ceftazidime-avibactam is combined with piperacillin-tazo

114 oving meropenem, ceftolozane-tazobactam, and ceftazidime-avibactam is unknown.

115 in vivo validation, piperacillin-tazobactam-ceftazidime-avibactam may represent salvage therapy for

116 an Enterobacterales isolate collection with ceftazidime-avibactam MIC values near the breakpoints.

117 counterpart), were tested against a panel of ceftazidime-avibactam nonsusceptible Bcc and B. gladioli

118 Clinical cure rates with ceftazidime-avibactam plus metronidazole and meropenem,

119 The clinical cure rate with ceftazidime-avibactam plus metronidazole for ceftazidime

120 randomization, assessed by noninferiority of ceftazidime-avibactam plus metronidazole to meropenem in

121 The safety profile of ceftazidime-avibactam plus metronidazole was consistent

122 Ceftazidime-avibactam plus metronidazole was noninferior

123 Ceftazidime-avibactam plus metronidazole was noninferior

124 Efficacy and safety of ceftazidime-avibactam plus metronidazole were compared w

125 Ceftazidime-avibactam resistance was detected in 30% (3/

126 ternative antibiotic combination to overcome ceftazidime-avibactam resistance.

127 ary endpoint) occurred in 304 of 393 (77.4%) ceftazidime-avibactam vs 296 of 417 (71.0%) doripenem pa

128 Noninferiority of ceftazidime-avibactam vs doripenem was demonstrated for

129 Ceftazidime-avibactam was highly effective for the empir

130 INTERPRETATION: Ceftazidime-avibactam was non-inferior to meropenem in t

131 however, coadministration of fosfomycin with ceftazidime-avibactam yielded a lower frequency of resis

132 values, and MIC(90) values were as follows: ceftazidime-avibactam, 92.8%, 2 mug/ml, and 8 mug/ml; im

133 as tested: ceftazidime, imipenem, meropenem, ceftazidime-avibactam, and imipenem-relebactam (an inves

134 8 to 2018 was evaluated against ceftazidime, ceftazidime-avibactam, chloramphenicol, delafloxacin, le

135 ug-resistant Gram-negative bacteria (namely, ceftazidime-avibactam, plazomicin, and meropenem-vaborba

136 ing an example of the development process of ceftazidime-avibactam, we propose a strategy for a new r

137 Herein, ceftazidime-avibactam-fosfomycin combination therapy aga

138 h" to combination chemotherapy, we show that ceftazidime-avibactam-fosfomycin has the potential to of

139 fection model using a high bacterial burden, ceftazidime-avibactam-fosfomycin significantly reduced t

140 Thus, the combination of ceftazidime-avibactam-fosfomycin was superior to either

141 erived cephalosporinase (PDC), and MurA with ceftazidime-avibactam-fosfomycin, antimicrobial suscepti

142 s for meropenem, ceftolozane-tazobactam, and ceftazidime-avibactam.

143 ae (CRE)-infected patients were treated with ceftazidime-avibactam.

144 id, oritavancin, ceftolozane-tazobactam, and ceftazidime-avibactam.

145 The strain was highly resistant to ceftazidime-avibactam.

146 No new safety concerns were identified for ceftazidime-avibactam.

147 using two FDA-approved drugs: aztreonam and ceftazidime-avibactam.

148 ver, 10% of the isolates tested resistant to ceftazidime-avibactam.

149 ns of meropenem, ceftolozane-tazobactam, and ceftazidime-avibactam.

150 a-lactamase inhibitor (BL-BLI) combinations, ceftazidime/avibactam (CZA) and ceftolozane/tazobactam (

151 Ceftazidime/avibactam and meropenem/vaborbactam are chan

152 In summary, ceftolozane/tazobactam and ceftazidime/avibactam are 2 new second-generation cephal

153 Ceftolozane/tazobactam and ceftazidime/avibactam are 2 novel beta-lactam/beta-lacta

154 Both ceftolozane/tazobactam and ceftazidime/avibactam are only available as intravenous

155 Ceftazidime/avibactam is also active against carbapenem-

156 ationalize the observed clinical efficacy of ceftazidime/avibactam plus aztreonam as combination ther

157 Ceftolozane/tazobactam, ceftazidime/avibactam, and telavancin all carry precauti

158 eta-lactamase inhibitor combinations such as ceftazidime/avibactam, no class B carbapenemases were mi

159 the transition-state analogue suggests that ceftazidime blocks formation of the tetrahedral transiti

160 the WT and P167S/D240G variant with acylated ceftazidime both favor a closed conformation not conduci

161 stance to the third-generation cephalosporin ceftazidime by an uncommon covalent-trapping mechanism.

162 rmational change occurred in the turnover of ceftazidime by KPC-2, but not the R164S variant, providi

163 Ceftazidime cannot adopt a conformation competent for ca

164 7.4%), 42/210 (20%), and 55/344 (16%) in the ceftazidime, carbapenem, and piperacillin-tazobactam gro

165 We aimed to compare ceftazidime, carbapenems, and piperacillin-tazobactam as

166 s or adverse events was demonstrated between ceftazidime, carbapenems, and piperacillin-tazobactam as

167 nism of resistance to the cephalosporin drug ceftazidime caused by loss of a penicillin-binding prote

168 entiate the activity of cefotaxime (CTX) and ceftazidime (CAZ) against resistant clinical isolates (M

169 l patient surveillance cultures screened for ceftazidime (CAZ) resistance, antibiotic and hospital ex

170 (IPM), meropenem (MEM), ertapenem (ERT), and ceftazidime (CAZ).

171 ening criteria for potential ESBL producers (ceftazidime [CAZ] or cefotaxime [CTX] MICs were > or =2

172 tis to vancomycin (VAN), amikacin (AMK), and ceftazidime (CEF).

173 ected to cefazolin, ceftriaxone, cefotaxime, ceftazidime, cefepime, and aztreonam agar dilution MIC d

174 our antimicrobial agents, namely, cefazolin, ceftazidime, cefepime, and doripenem, were determined by

175 ndard doses: meropenem, imipenem-cilastatin, ceftazidime, cefepime, piperacillin/tazobactam, and cipr

176 , using broth microdilution methodology with ceftazidime, cefotaxime, cefepime, cefpodoxime, and aztr

177 MD), and those isolates for which the MIC of ceftazidime, cefotaxime, ceftriaxone, or aztreonam was >

178 gram from 2008 to 2018 was evaluated against ceftazidime, ceftazidime-avibactam, chloramphenicol, del

179 For a ceftazidime, ceftriaxone, or cefotaxime MIC of > or =2 m

180 phylococcus aureus killed during imipenem or ceftazidime chemotherapy in mice elicited an early relea

181 Ps, as suggested by a comparison of the PBP3/ceftazidime complex and the Escherichia coli PBP1b/cefto

182 of three beta-lactams (oxacillin, cefepime, ceftazidime) complexes with PBP2a-each with the beta-lac

183 Ceftazidime contains a large, bulky side chain that does

184 Ceftazidime disks with and without clavulanic acid (CLAV

185 is usually treated with two or more weeks of ceftazidime followed by oral antibiotics for three to si

186 ceftazidime-resistant mutants, and restoring ceftazidime for treatment.

187 o once or three-times daily tobramycin (with ceftazidime) for 14 days.

188 acy if given once or three-times daily (with ceftazidime) for pulmonary exacerbations of cystic fibro

189 All strains were resistant to ceftazidime, gentamicin, and tobramycin; 96% were resist

190 addition to determining MICs of antibiotics (ceftazidime, gentamicin, meropenem, vancomycin and linez

191 harmacy showed additivity when gentamicin or ceftazidime/gentamicin were combined with meropenem to t

192 iotics combinations (gentamicin/meropenem or ceftazidime/gentamicin/meropenem) at different dosages w

193 oxime, cefotaxime, cefepime, cefodizime, and ceftazidime; group B, positive responses to aminocephalo

194 lyze cephalosporins including cefuroxime and ceftazidime has been determined by X-ray crystallography

195 hanisms of action-meropenem, gentamicin, and ceftazidime-highlighting the versatility of this platfor

196 o a greater degree than were ceftolozane and ceftazidime; however, concentrations for all antibiotics

197 termined that acylation is rate-limiting for ceftazidime hydrolysis by KPC-2, whereas deacylation is

198 ese mutations would be predicted to increase ceftazidime hydrolysis further, the P167S/D240G combinat

199 region of the P99 enzyme result in increased ceftazidime hydrolysis suggesting the loop is an importa

200 240G double mutant enzyme exhibits decreased ceftazidime hydrolysis, lower thermostability, and decre

201 the residue positions that are critical for ceftazidime hydrolysis.

202 A was defined by resistance to piperacillin, ceftazidime, imipenem, and FQ.

203 spectrum beta-lactams, aztreonam, cefepime, ceftazidime, imipenem, and piperacillin-tazobactam, were

204 tance to two antibiotics among piperacillin, ceftazidime, imipenem, colistine, and fluoroquinolones (

205 following antipseudomonal agents was tested: ceftazidime, imipenem, meropenem, ceftazidime-avibactam,

206 -piperacillin, imipenem-cefotaxime, imipenem-ceftazidime, imipenem-piperacillin-tazobactam, and imipe

207 eatment included intravitreal vancomycin and ceftazidime in 59 of 63 (94%) eyes and intravitreal vanc

208 stance to the third generation cephalosporin ceftazidime in bacterial pathogens expressing AmpC.

209 in the level of resistance to the antibiotic ceftazidime in comparison to that of the parental wild-t

210 Resistance to moxifloxacin and ceftazidime in cultured isolates at baseline and monthly

211 tient-days ranged from 0.2 (for colistin and ceftazidime in P. aeruginosa and for carbapenems in Kleb

212 substrate, reveals that the conformation of ceftazidime in the active site differs from that of subs

213 omycin was significantly more effective than ceftazidime in the treatment of nosocomial SBP (86.7 vs.

214 to compare meropenem plus daptomycin versus ceftazidime in the treatment of nosocomial SBP.

215 TEM(pTZ19-3) Glu166Arg/Met182Thr mutant for ceftazidime increased by at least 110-fold and the acyla

216 ation cephalosporins, such as cefotaxime and ceftazidime, increasing hospital mortality rates.

217 Ceftazidime/inhibitor resistant mutants hyperproduce L1,

218 The beta-lactam antibiotic ceftazidime is one of the handful of drugs with proven c

219 mary treatment with vancomycin combined with ceftazidime is supported by this study.

220 either anti-CD14 monoclonal antibody without ceftazidime, isotype control monoclonal antibody without

221 hogens to the third generation cephalosporin ceftazidime; it may serve as a lead compound for drug di

222 ga-loop to an open conformation accommodates ceftazidime leading to enhanced catalysis.

223 hat the best of the reversible inhibitors, a ceftazidime-like boronic acid compound, binds to CTX-M-1

224 ent, enhanced efficacy versus both strains - ceftazidime + meropenem and aztreonam + meropenem.

225 ed resistance to the oxyimino-cephalosporin, ceftazidime (minimum inhibitory concentration; 32-->128

226 1), Meropenem/Vancomycin (n = 16, P = .003), Ceftazidime (n = 10, P = .03), or multiple systemic anti

227 Five antibiotics were examined: Ceftazidime (n=2942), Gentamicin (n=4360), Imipenem (n=2

228 inutes to different antibiotics, gentamicin, ceftazidime, nitrofurantoin, nalidixic acid, ofloxacin.

229 ) and Pseudomonas aeruginosa (30%); 28% were ceftazidime-non-susceptible.

230 for the primary efficacy analyses; 19.6% had ceftazidime-nonsusceptible baseline pathogens.

231 h treatments showed similar efficacy against ceftazidime-nonsusceptible pathogens.

232 ory test was positive; i.e., the BMD MICs of ceftazidime or cefotaxime decreased by >/=3 doubling dil

233 n zone diameters increased by >/=5 mm around ceftazidime or cefotaxime disks in the presence of CA.

234 carbapenem-sparing regimens, suggests using ceftazidime or piperacillin-tazobactam for treating susc

235 phylococcus aureus, a second drug was added (ceftazidime or piperacillin/tazobactam for P. aeruginosa

236 en, inflammation level, and effectiveness of ceftazidime or subtherapeutic colistin to treat the infe

237 beta-lactamase resistant beta-lactams (e.g., ceftazidime) or avoid mechanism-based inhibitors (e.g.,

238 group (cefuroxime, cefotaxime, ceftriaxone, ceftazidime, or aztreonam) was associated with bacteremi

239 tazidime, anti-CD14 monoclonal antibody with ceftazidime, or isotype control antibody with ceftazidim

240 95% confidence interval [CI], 0.52-2.46, for ceftazidime; OR, 1.3; 95% CI, 0.67-2.51, for piperacilli

241 terial isolates to vancomycin, amikacin, and ceftazidime over a 23-year period.

242 ect, which enhances conversion of drugs like ceftazidime, penicillins, and imipenem.

243 tazidime-avibactam (a combination of 2000 mg ceftazidime plus 500 mg avibactam, administered via a 2-

244 es for ampicillin and nitrocefin, hydrolyzed ceftazidime poorly, and hydrolyzed imipenem more efficie

245 ncoded by smlt0009 in S. maltophilia, confer ceftazidime resistance and smlt0009 mutants have reduced

246 hat the R164S substitution in KPC-2 enhances ceftazidime resistance by proceeding through "covalent t

247 Both inhibitors reverse ceftazidime resistance in S. maltophilia because, unlike

248 ing 1992 and 1993 and a two-fold increase in ceftazidime resistance of the Pseudomonas species.

249 common 54-kilobase plasmid, which conferred ceftazidime resistance via the ESBL TEM-10, and mediated

250 wild-type B. pseudomallei demonstrated that ceftazidime resistance was due to deletion of a gene enc

251 egies to a population with 15% prevalence of ceftazidime-resistance and 5% imipenem-resistance, RMD p

252 vancomycin-resistant enterococci (VRE), and ceftazidime-resistant (CAZ(r)) and ciprofloxacin-resista

253 hospital patients infected or colonized with ceftazidime-resistant E coli, K pneumoniae, or both were

254 urvey, 18 of 39 patients were colonized with ceftazidime-resistant E coli; prior receipt of ciproflox

255 ere were fewer acquired infections caused by ceftazidime-resistant Enterobacteriaceae (0.8 per thousa

256 alternative to carbapenems in patients with ceftazidime-resistant Enterobacteriaceae and P aeruginos

257 plicated intra-abdominal infection caused by ceftazidime-resistant Enterobacteriaceae or Pseudomonas

258 ents who were infected and/or colonized with ceftazidime-resistant Escherichia coli, Klebsiella pneum

259 nalysed in all patients who had at least one ceftazidime-resistant Gram-negative pathogen, as confirm

260 complicated intra-abdominal infection due to ceftazidime-resistant Gram-negative pathogens.

261 ceftazidime-avibactam plus metronidazole for ceftazidime-resistant infections was comparable to that

262 pe was abolished, disabling the emergence of ceftazidime-resistant mutants, and restoring ceftazidime

263 y confined to an outbreak of gentamicin- and ceftazidime-resistant organisms caused by contaminated a

264 ctions caused by ceftazidime-susceptible and ceftazidime-resistant pathogens.

265 case of chronic endophthalmitis caused by a ceftazidime-resistant Rhizobium radiobacter strain in a

266 genomic deletion comprising 49 genes in the ceftazidime-resistant strains.

267 We also show that ceftazidime-resistant TonB mutants are cross-resistant t

268 tazidime-susceptible isolates and subsequent ceftazidime-resistant variants.

269 ection of vancomycin-amikacin and vancomycin-ceftazidime, respectively, which resulted in complete re

270 ptible by routine testing to ceftriaxone and ceftazidime, respectively.

271 Vancomycin and ceftazidime seem to be excellent empiric antibiotics for

272 -negative strains tested, all 12 (100%) were ceftazidime-sensitive.

273 structure to create additional space for the ceftazidime side chain.

274 Infections caused by ceftazidime sodium-resistant gram-negative bacteria that

275 es of mutant enzymes with covalently trapped ceftazidime suggested that a change of an active-site Om

276 acy was similar against infections caused by ceftazidime-susceptible and ceftazidime-resistant pathog

277 imilar to the regimen's own efficacy against ceftazidime-susceptible infections (82.0%).

278 six patients with melioidosis found initial ceftazidime-susceptible isolates and subsequent ceftazid

279 panel type 32) that included cefotaxime and ceftazidime tested alone or with a fixed concentration o

280 me CTX-M-16 is eightfold more active against ceftazidime than the pseudo-wild-type CTX-M-14 but is 1.

281 mutant formed a stable covalent complex with ceftazidime that remained intact for the entire duration

282 r 5-FC was significantly more effective than ceftazidime, the current antibiotic of choice, for impro

283 When combined with ceftazidime, the novel non-beta-lactam beta-lactamase in

284 as aeruginosa, in the presence or absence of ceftazidime therapy, and with Klebsiella pneumoniae.

285 period 1 (baseline period) (1,323 patients), ceftazidime; time period 2 (1,243 patients), ciprofloxac

286 e in the minimal inhibitory concentration of ceftazidime to 64 mug/mL.

287 Binding of either carbenicillin or ceftazidime to purified PBP3 increases the thermostabili

288 (11/18) versus 0% (0/10) in Pseudomonas- and ceftazidime-treated rats; and 64% (9/14) versus 13% (2/1

289 This provides one explanation for ceftazidime treatment failure, and may be a frequent but

290 antibody-treated animals in the presence of ceftazidime treatment.

291 antimicrobial agents, including ampicillin, ceftazidime, trimethoprim-sulfamethoxazole, gentamicin,

292 s based on the reduction of imipenem (IP) or ceftazidime (TZ) MICs in the presence of EDTA or 2-merca

293 tazobactam (VM error, 9.3%; m error, 12.9%), ceftazidime (VM error, 6.2%; m error, 11.4%), cefepime (

294 Ceftazidime was the only agent to which a number of spec

295 dime and with a transition-state analogue of ceftazidime were determined by X-ray crystallography to

296 individual swab sites when mLAM plates with ceftazidime were inoculated after a 24-h enrichment peri

297 contained vancomycin and either aztreonam or ceftazidime were used as the selective medium.

298 efazolin, cefepime, and, to a lesser extent, ceftazidime, which neither have significant antienteroco

299 ption was B. pseudomallei in the presence of ceftazidime, which required >10 h of incubation.

300 cefotaxime more efficiently than the bulkier ceftazidime, with improved ESOC turnover by KPC-4 result